Bank of New York Mellon’s Tandem Diabetes Care TNDM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.31M Buy
352,161
+15,870
+5% +$277K ﹤0.01% 2411
2026
Q1
$6.45M Sell
336,291
-13,462
-4% -$293K ﹤0.01% 2177
2025
Q4
$7.69M Sell
349,753
-34,381
-9% -$620K ﹤0.01% 2085
2025
Q3
$4.66M Sell
384,134
-14,869
-4% -$201K ﹤0.01% 2364
2025
Q2
$7.44M Sell
399,003
-8,479
-2% -$168K ﹤0.01% 2050
2025
Q1
$7.81M Sell
407,482
-29,210
-7% -$855K ﹤0.01% 1988
2024
Q4
$15.7M Buy
436,692
+4,130
+1% +$140K ﹤0.01% 1699
2024
Q3
$18.3M Sell
432,562
-61,751
-12% -$2.62M ﹤0.01% 1625
2024
Q2
$19.9M Buy
494,313
+73,397
+17% +$3.06M ﹤0.01% 1583
2024
Q1
$14.9M Sell
420,916
-24,642
-6% -$660K ﹤0.01% 1740
2023
Q4
$13.2M Sell
445,558
-69,099
-13% -$1.43M ﹤0.01% 1828
2023
Q3
$10.7M Sell
514,657
-888
-0.2% -$24.4K ﹤0.01% 1909
2023
Q2
$12.7M Sell
515,545
-75,035
-13% -$2.41M ﹤0.01% 1814
2023
Q1
$24M Sell
590,580
-49,148
-8% -$2.03M 0.01% 1451
2022
Q4
$28.8M Sell
639,728
-14,080
-2% -$637K 0.01% 1342
2022
Q3
$31.3M Buy
653,808
+17,742
+3% +$973K 0.01% 1236
2022
Q2
$37.6M Buy
636,066
+22,319
+4% +$1.83M 0.01% 1159
2022
Q1
$71.4M Buy
613,747
+3,836
+0.6% +$448K 0.01% 860
2021
Q4
$91.8M Buy
609,911
+29,216
+5% +$3.94M 0.02% 751
2021
Q3
$69.3M Buy
580,695
+337,838
+139% +$37.2M 0.01% 907
2021
Q2
$23.7M Sell
242,857
-20,332
-8% -$1.81M ﹤0.01% 1637
2021
Q1
$23.2M Buy
263,189
+38,840
+17% +$3.61M ﹤0.01% 1627
2020
Q4
$21.5M Sell
224,349
-676
-0.3% -$69.7K ﹤0.01% 1594
2020
Q3
$25.5M Buy
225,025
+3,240
+1% +$340K 0.01% 1313
2020
Q2
$21.9M Sell
221,785
-39,918
-15% -$3.19M 0.01% 1392
2020
Q1
$16.8M Buy
261,703
+16,268
+7% +$1.14M 0.01% 1401
2019
Q4
$14.6M Sell
245,435
-9,326
-4% -$575K ﹤0.01% 1748
2019
Q3
$15M Buy
254,761
+7,831
+3% +$500K ﹤0.01% 1693
2019
Q2
$15.9M Buy
246,930
+4,907
+2% +$317K ﹤0.01% 1692
2019
Q1
$15.4M Sell
242,023
-8,233
-3% -$432K ﹤0.01% 1717
2018
Q4
$9.5M Buy
250,256
+39,264
+19% +$1.39M ﹤0.01% 1933
2018
Q3
$9.04M Buy
210,992
+6,313
+3% +$220K ﹤0.01% 2075
2018
Q2
$4.51M Buy
204,679
+155,314
+315% +$1.91M ﹤0.01% 2448
2018
Q1
$244K Buy
+49,365
New +$159K ﹤0.01% 3871
2017
Q4
Sell
-1,285
Closed -$9K 4396
2017
Q3
$9K Hold
1,285
﹤0.01% 4246
2017
Q2
$10K Sell
1,285
-4,425
-77% -$40.9K ﹤0.01% 4266
2017
Q1
$69K Sell
5,710
-14,453
-72% -$316K ﹤0.01% 4097
2016
Q4
$434K Sell
20,163
-45
-0.2% -$1.73K ﹤0.01% 3651
2016
Q3
$1.55M Sell
20,208
-1,259
-6% -$91.8K ﹤0.01% 2923
2016
Q2
$1.62M Sell
21,467
-758
-3% -$61K ﹤0.01% 2843
2016
Q1
$1.94M Sell
22,225
-193
-0.9% -$16.9K ﹤0.01% 2678
2015
Q4
$2.65M Buy
22,418
+41
+0.2% +$4.07K ﹤0.01% 2551
2015
Q3
$1.97M Buy
22,377
+816
+4% +$95K ﹤0.01% 2752
2015
Q2
$2.34M Buy
21,561
+2,170
+11% +$270K ﹤0.01% 2802
2015
Q1
$2.45M Buy
19,391
+1,138
+6% +$148K ﹤0.01% 2722
2014
Q4
$2.32M Sell
18,253
-3,655
-17% -$507K ﹤0.01% 2775
2014
Q3
$2.94M Buy
21,908
+2,214
+11% +$310K ﹤0.01% 2618
2014
Q2
$3.2M Buy
19,694
+4,926
+33% +$838K ﹤0.01% 2620
2014
Q1
$3.26M Sell
14,768
-29
-0.2% -$7.39K ﹤0.01% 2565
2013
Q4
$3.81M Buy
+14,797
New +$3.39M ﹤0.01% 2465

Other funds holding TNDM

Bank of New York Mellon's TNDM Position: Q2 2026 in Review

Bank of New York Mellon increased its Tandem Diabetes Care (TNDM) stake by 4.7% in Q2 2026, buying an estimated $277K and bringing the position to 352,161 shares worth $5.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2411.

Bank of New York Mellon first reported a position in TNDM in Q4 2013 and has held it in 50 quarters since. The position peaked at $91.8M in Q4 2021. 150 funds tracked by Wall St. Rank hold TNDM as of Q2 2026.

  • Bank of New York Mellon held 352,161 shares of Tandem Diabetes Care worth $5.31M as of Q2 2026.
  • Bank of New York Mellon bought 15,870 Tandem Diabetes Care shares in Q2 2026, an estimated $277K.
  • Tandem Diabetes Care made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2411 holding.
  • Bank of New York Mellon first reported a position in Tandem Diabetes Care in Q4 2013 and has held it in 50 quarters since.
  • Bank of New York Mellon's Tandem Diabetes Care position peaked at $91.8M in Q4 2021.
  • 150 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.